Given the possible importance of anti-citrullinated peptide/protein antibodies (ACPA) for initiation and progression of rheumatoid arthritis (RA), extended knowledge about the different isotypes and subclasses is important. In the present study, we analysed the immunoglobulin (Ig)G subclasses regarding reactivity against cyclic citrullinated peptides (anti-CCP) among 504 clinically well-characterized patients with recent-onset RA in relation to smoking habits, shared epitope (SE) status and IgA and panIgG anti-CCP antibodies. All patients, regardless of pan-IgG anti-CCP status, were analysed for IgG1-4 CCP reactivity. Sixty-nine per cent were positive in any IgG anti-CCP subclass, and of these 67% tested positive regarding IgG1, 35% IgG2, 32% IgG3, and 59% IgG4 anti-CCP. Among ever-smokers the percentages of IgG2 anti-CCP (P 5 0Á01) and IgA anti-CCP (P 5 0Á002)-positive cases were significantly higher compared to neversmokers. A positive IgG anti-CCP subclass -negative cases. Combining SE and smoking data revealed that IgG1 and IgG4 anti-CCP were the IgG anti-CCP isotypes associated with expression of SE, although the lower number of patients positive for IgG2 or IgG3 anti-CCP could, however, have influenced the results. High levels of IgG2 anti-CCP were shown to correlate with expression of the 'non-SE' allele human leucocyte antigen (HLA)-DRB1*15. In conclusion, in this study we describe different risk factor characteristics across the IgG anti-CCP subclasses, where IgG2 appears similar to IgA anti-CCP regarding the predominant association with smoking, while IgG1 and IgG4 related more distinctly to the carriage of SE genes.
Introduction
Rheumatoid arthritis (RA) is a common chronic inflammatory disease, subdivided into rheumatoid factor (RF) and/or anti-citrullinated protein antibody (ACPA)-positive and RF/ACPA-negative cases [1] . Although not stipulated in the 1987 and 2010 RA classification criteria [2, 3] , a positive RF test refers usually to immunoglobulin (Ig)M-class antibodies against IgG-Fc (human, rabbit, horse and a multitude of other species), whereas a positive ACPA test refers generally to IgG-class antibodies. The majority of RF-positive RA patients are also ACPA-positive and vice versa, and these patients generally have a more severe disease course and outcome compared to the RF-and ACPAseronegative RA cases [4] [5] [6] [7] . The most commonly used ACPA tests detect IgG-class antibodies directed against 'the 2nd generation cyclic citrullinated peptide' (CCP2) [8] .
It is well known that cigarette smoking [9] [10] [11] [12] [13] [14] and genetic carriage of human leucocyte antigen (HLA)-DR/ 'shared epitope' (SE) [15, 16] are risk factors for RA development, and that the combination of SE carriage and smoking increases markedly the risk of developing ACPA-positive RA [17] [18] [19] [20] . Apart from HLA-DRB1/SE, the 'non-SE' allele HLA-DRB1*15 has also been indicated to promote high levels of ACPA [21] .
Bronchoalveolar lavage (BAL) cells from smokers display more extensive protein-citrullination compared to BAL cells from non-smokers [18] , due presumably to the excessive cell damage following the exposure of toxic contents from cigarettes. In patients with recent-onset RA, the occurrence of circulating IgG anti-CCP was shown to associate with parenchymal lung abnormalities and site-specific citrullination, and antibodies (IgG-and IgA-RF as well as IgG anti-CCP) were enriched in the lungs [22] . We have shown recently that cigarette smoking associates with circulating IgA anti-CCP in RA, but not with IgG anti-CCP [23] .
The dynamics and consequences of IgG responses relate to the degree of T cell dependency, IgG subclass predominance, Fc-gamma receptor (FcgR) affinity and FcgR-mediated cell activation/inhibition [24] . IgG subclasses 1-3 all have cell-activating properties after ligating FcgRI, IIA IIIA or IIIB exposed on cell surfaces, whereas IgG1 has a down-regulating/inhibitory effect after ligation to cell surface FcgRIIB [24] . Depending on the circumstances, IgA-class antibodies can exert dual effects after ligation to cell-surface FcRs, and can thus be both pro-and anti-inflammatory [25] . In contrast to IgG-class antibodies, IgA does not activate complement via the classical pathway [26] . Like IgA, IgG4 can exert anti-inflammatory effects due to its unique bi-antigen recognition after undergoing Fab-arm exchange [27] . The anti-inflammatory effect of IgG4 has been suggested to be due to limitation of immune complex formation [27] .
Total IgG anti-CCP is analysed in clinical praxis, whereas IgM and IgA anti-CCP antibodies are usually not [28, 29] . We have shown previously that the presence of circulating IgA antibodies to citrullinated antigens, in combination with high-level IgG-ACPA, is more common in recentonset RA patients with a severe disease course compared to patients with IgG-class antibodies alone [28, 30] . Others have shown that the presence of IgA anti-CCP at high levels increases the risk of developing RA among patients with undifferentiated arthritis [29] .
The present study was undertaken to shed light upon the different IgG anti-CCP subclasses in recentonset RA in relation to cigarette smoking, SE and IgA anti-CCP.
Materials and methods

Subjects
A total of 504 clinically well-characterized patients with recent-onset RA (< 12 months since first observed jointswelling, according to the patients' judgement) were recruited to the Swedish TIRA-2 inception cohort (Swedish acronym for 'Early Intervention in Rheumatoid Arthritis') 2006-09, based on: Patient characteristics at inclusion are summarized in Table  1 . The patients had not received disease-modifying antirheumatic drugs or corticosteroids prior to the initial blood sampling at the first visit. Ethylenediamine tetraacetic acid (EDTA) blood and serum samples were taken from all participants and stored at 2708C until analysed. Serum samples from 101 healthy blood donors, 51 women and 50 men, served as controls for the antibody analyses.
Smoking habits
Data on cigarette smoking habits (prior to the first symptoms of arthritis) were available for 263 of the RA patients. Fifty-seven emanated from medical records of RA patients included at the Falun hospital. The remaining 206 TIRA-2 RA cases participated in the Stockholm-based 'Epidemiological Investigation of Rheumatoid Arthritis' (EIRA) project (Karolinska Institute, Stockholm, Sweden), where smoking habits were available from questionnaires [18] . The smoking data were categorized into ever-smokers (current and former smokers) and never-smokers. 
IgG anti-CCP subclass analyses
The levels of IgG anti-CCP subclasses were measured in all patients, regardless of pan-IgG anti-CCP status, using an in-house-modified enzyme-linked immunosorbent assay (ELISA) kit (Euro-Diagnostica, Malm€ o, Sweden). Serum samples were diluted 1 : 50, added to CCP-coated microtitre plates and incubated for 1 h. Following washing, a monoclonal mouse anti-human antibody specific for the respective IgG subclass was used: IgG1, 2 and 4 from AbD Serotec (Kidlington, UK; IgG1 clone 2C11; IgG2 clone 3C7 and IgG4 clone HP 6023). Antibodies against IgG3 (clone NI 86; HP 6080) were obtained from Nordic Immunology (Eindhoven, the Netherlands). The monoclonal antibody preparations were in-house titrated and regarded optimal at the following dilutions: 1 : 2000 for IgG1, 1 : 5000 for IgG2 and 1 : 10 000 for IgG3 and IgG4, respectively. Alkaline-phosphatase-conjugated polyclonal rabbit antimouse immunoglobulins were used as detection antibody (Dako, Glostrup, Denmark), p-nitrophenol phosphate solution as substrate solution (AbD Serotec) and 1 M NaOH as stop solution. The plates were read at 405 nm, with 650 nm as reference wavelength (TECAN Sunrise, software: Magellan version 7.1; Tecan Nordic AB, M€ olndal, Sweden). A seven-step serial dilution of known high-level IgG anti-CCP patient sera for the respective IgG subclass was used for standard curve calculations. IgG anti-CCP subclass data were available from 504 patients. Serum samples were analysed in duplicate and the cut-off limit for positivity was set at the 99th percentile of the 101 healthy blood donor control sera (cut-off: IgG1 5339 U/ml, IgG2 3759 U/ml, IgG3 7818 U/ml and IgG4 2080 U/ml).
IgA and pan-IgG anti-CCP analyses
IgA and pan-IgG anti-CCP were analysed in baseline serum samples by means of fluoroenzyme-immunoassay [EliA TM ; Thermo Fisher Scientific (PhaDia AB, Uppsala, Sweden)]. The cut-off level for a positive IgA and pan-IgG anti-CCP test was set at the 99th percentile (cut-off IgA: 1Á6 U/ml, pan-IgG: 7 U/ml) of the 101 healthy blood donor control sera. IgA and pan-IgG anti-CCP data were available from 497 patients. All but nine of the IgA-positive patients were positive in ! 1 anti-CCP IgG subclass. Six patients were positive in pan-IgG anti-CCP but not in any of the IgG subclasses, and six patients were negative in pan-IgG anti-CCP but positive in any of the IgG subclasses.
RF analyses
Agglutinating RF tests were performed in a clinical routine setting at each local laboratory associated with the participating rheumatology unit.
Statistical analyses
Statistical analyses were performed using Prism version 6 (Graphpad V R Software Inc., version 6.0c, La Jolla, CA, USA) and SPSS (IBM Corp., Armonk, NY, USA). P-values for differences in proportions of IgG anti-CCP subclasses were calculated using the two-tailed Fisher's exact test. Differences with a P-value < 0Á05 were regarded as significant. Pvalues for differences in IgG anti-CCP subclass levels were analysed in IgG anti-CCP-positive cases using the MannWhitney test. Due to the high proportion of patient samples exceeding the highest standard point in pan-IgG (44%) and IgG1 (46%), we used IgG2 (3%), IgG3 (9%), IgG4 (7%) and IgA (0%) to analyse correlations of HLA-DRB1*15 and anti-CCP levels. P-values < 0Á05 were regarded as significant. Two-way analysis of variance (ANOVA) was used to analyse interactions between SE and smoking habits and the levels of pan-IgG, IgA and IgG subclass anti-CCP in anti-CCP-positive and -negative patients. A P-value < 0Á05 was regarded as significant. The correlation between subclass usage and the levels of pan-IgG anti-CCP was analysed using Spearman's correlation coeffient. A P-value < 0Á05 was regarded as significant.
Ethics approval
The participating patients gave their written informed consent. The regional ethical review board in Link€ oping, Sweden approved the study protocol (decision number M168-05).
Results
Distribution of IgG1-4 anti-CCP subclasses and IgA anti-CCP
Of the 504 TIRA-2 patients, 69% were positive in ! 1 of any anti-CCP IgG subclass. For the respective subclass, 67% were IgG1-positive, 35% IgG2-positive, 32% IgG3-positive and 59% IgG4-positive (Fig. 1 ). This pattern (IgG1 > IgG4 > IgG2 % IgG3) was seen generally throughout the study. Data on pan-IgG anti-CCP were available from 497 patients, and among these 69% were pan-IgG anti-CCP-positive.
The overall IgG subclass repertoire, among the 69% patients testing positive in ! 1 of any IgG anti-CCP subclass, revealed that 12% were positive in one subclass, 30% positive in two, 23% positive in three and 35% positive in all four (data not shown). A strong correlation was seen between the number of IgG subclasses present and the concentration of pan-IgG anti-CCP (r 5 0Á90, P < 0Á0001). All patients testing positive in ! 2 IgG anti-CCP subclasses were pan-IgG-positive and IgG1-positive, and all except 12 were IgG4-positive (data not shown).
Of 497 patients, 253 (51%) tested positive for IgA anti-CCP antibodies (Fig. 1) . All but nine of these IgA-positive patients were also positive in ! 1 anti-CCP IgG subclass, and all but 10 were pan-IgG-positive (data not shown). In the IgA-positive patients IgG2 (P 5 0Á001) and IgG3 (P < 0Á001) anti-CCP were significantly more frequent than IgG1 and IgG4 anti-CCP (data not shown).
IgG anti-CCP subclass and IgA anti-CCP versus smoking
Among the 263 patients, with smoking data available, 69% tested positive for ! 1 IgG anti-CCP subclass. Sixty-four per cent were ever-smokers and, of these, 72% were panIgG anti-CCP-positive and 71% were positive in ! 1 IgG anti-CCP subclass. Among the never-smokers, 65% were pan-IgG anti-CCP-positive and 65% tested positive for ! 1 IgG anti-CCP subclasses (Fig. 2) .
When investigating IgG anti-CCP subclasses separately, IgG1 anti-CCP was the most frequent, followed by IgG4, IgG2 and IgG3 anti-CCP in ever-smoker as well as neversmokers. However, the proportion of IgG2 anti-CCPpositive cases differed significantly between ever-and never-smokers (P 5 0Á01). The fractions of IgG1, IgG3 and IgG4 anti-CCP did not differ significantly between everand never-smokers (Fig. 2) .
IgA anti-CCP-positive cases were significantly more frequent among ever-smokers compared to never-smokers (P 5 0Á002) (Fig. 2) .
IgG anti-CCP subclass and IgA anti-CCP versus SE and HLA-DRB1*15
Data on SE status were available from 502 patients. Among the 370 patients that were SE carriers (SE 1 ), 78% were pan-IgG anti-CCP-positive and 77% tested positive for ! 1 IgG anti-CCP subclass. Among the 132 SE-negative (SE  -) patients, 47% were pan-IgG anti-CCP-positive and 47% were positive in ! 1 IgG anti-CCP subclass (Fig. 3) . The proportion of IgG anti-CCP-positive cases in the SE 1 subgroup was significantly higher compared to the SE -subgroup, regardless of subclass (P < 0Á0001 for IgG1 and IgG4, P 5 0Á02 for IgG2 and P 5 0Á003 for IgG3). Taken together, a positive anti-CCP subclass test in any of the IgG anti-CCP subclasses was significantly more common in the SE 1 group compared to the SE -cases (Fig. 3) . The same was seen regarding IgA-class antibodies, where the fraction of anti-CCP-positive patients was higher within the SE 1 subgroup compared to the SE -subgroup (P < 0Á0001) (Fig. 3) . Data on HLA-DRB1*15 were available from 502 patients, 106 of whom were carriers. The status regarding IgG anti-CCP subclass distribution did not differ between HLA-DRB1*15 carriers and non-carriers. However, when comparing serum levels of IgG anti-CCP antibody subclasses among patients testing positive in the respective IgG subclass, HLA-DRB1*15 carriers showed higher average levels of IgG2 anti-CCP (P 5 0Á007) (Fig. 4a) . This was not seen for IgG3 anti-CCP or IgA anti-CCP, and only a trend was noted for IgG4 anti-CCP (P 5 0Á07) (Fig. 4a,b) . Pan-IgG and IgG1 anti-CCP levels were not analysed in relation to HLA-DRB1*15 due to the high proportion of patient samples exceeding the highest standard point in the ELISA.
IgG anti-CCP subclass and IgA anti-CCP versus smoking and SE Data on the combination of smoking habits and SE status were available from 262 patients, 121 of whom were SE 1 ever-smokers, 46 were SE -ever-smokers, 63 were SE 1 never-smokers and 32 were SE -never-smokers (data not shown).
Compared to SE -cases, the fraction of patients positive for SE 1 and pan-IgG anti-CCP (Fig. 5a ) or with ! 1 IgG anti-CCP subclass (Fig. 5b) was larger both among eversmokers (P 5 0Á0009, P 5 0Á0004, respectively) and neversmokers (P 5 0Á0005, P 5 0Á003, respectively). The fraction of IgG1 anti-CCP-positive cases among SE 1 patients was larger among ever-smokers (P 5 0Á0005) and never-smokers (P 5 0Á0007) compared to the SE -cases (Fig. 5c ). The fraction of IgG2 anti-CCP-positive cases was higher among SE 1 ever-smokers compared to SE -eversmokers (P 5 0Á02). Interestingly, the SE 1 subgroup showed a trend towards a higher fraction of IgG2 anti-CCP-positive cases among ever-smokers compared to never-smokers (P 5 0Á06). The same was seen when SE 1 was compared to SE -among never-smokers (P 5 0Á06) (Fig. 5e) . The fraction of SE 1 cases testing positive for IgG4 anti-CCP was higher both among ever-smokers (P 5 0Á001) and never-smokers (P 5 0Á03) compared to the SE -negative cases (Fig. 5f ).
The fraction of IgA anti-CCP-positive cases was significantly higher among SE 1 compared to SE -cases regardless of smoking habits (P 5 0Á0008 for ever-smokers and P 5 0Á007 for never-smokers). A difference correlating with smoking habits was seen among SE 1 cases, where eversmokers presented a higher proportion of IgA anti-CCPpositive cases compared to never-smokers (P 5 0Á02) (Fig.  5g) . The interaction between SE and smoking and the levels of the different anti-CCP isotypes and subclasses were also analysed using ANOVA, but no statistical significant difference could be shown (data not shown).
IgG anti-CCP subclasses and RF
Of the 504 TIRA-2 patients, 91% tested positive for ! 1 anti-CCP IgG subclass as well as for RF. For the respective subclasses, 90% were IgG1-and RF-positive, 48% IgG2-and RF-positive, 47% IgG3-and RF-positive and 79% IgG4-and RF-positive. Data on IgA and pan-IgG anti-CCP were available from 497 patients, 65% of whom were IgA anti-CCP-and RF-positive and 92% were pan-IgG anti-CCP-and RF-positive. All patients positive for RF were more frequently anti-CCP-positive regardless of isotype and subclass compared to RF-negative patients (P < 0Á0001) (Fig. 6) .
Discussion
Given the potential contribution of different ACPAs to the development and progression of RA, extended information about the different isotypes and IgG subclasses is important. In the present study we aimed to pin-point usage of the four IgG subclasses among 504 recent-onset RA patients in relation to smoking habits, SE status and circulating IgA anti-CCP. We found that all IgG anti-CCP subclasses associated with SE, but when smoking was taken into account only IgG1 and IgG4 anti-CCP associated with SE. IgG2 anti-CCP alone associated with smoking.
To identify serum anti-CCP-positive RA patients, we applied a strict cut-off level at the 99th percentile among 101 blood donors, referring to anti-CCP of all four IgG subclasses as well as to IgA anti-CCP. As reported previously by Chapuy-Regaud et al. [31] (anti-citrullinated fibrin antibodies) and Verpoort et al. [29] (anti-CCP), we confirmed that IgG4 anti-CCP was almost as frequent (59%) as IgG1 (67%), whereas the occurrence rates of IgG2 (32%) and IgG3 (32%) anti-CCP were considerably lower. Others have reported the presence of IgG1, IgG3 and IgG4 anti-viral citrullinated peptide/histone citrullinated peptide in RA patients, while the presence of IgG2 anti-viral citrullinated peptide/histone citrullinated peptide was negligible [32] . The discrepancy between the present study and the study by Panza et al. could be due to the use of different antigens in the antibody analyses, or that the patients were in different stages of the disease. Circulating IgA anti-CCP was recorded in 51% of the cases. However, the detection method does not allow direct comparisons of absolute serum levels of the different anti-CCP antibody isotypes and subclasses.
Looking separately at IgG-and IgA-ACPA in relation to SE and smoking habits, it is clear from previous research that IgG-ACPA formation (without subclass specification) is associated with HLA-DRB1/SE but not with cigarette smoking, whereas IgA-ACPA relates to cigarette smoking but not to HLA-DRB1/SE [23] . In the current study we present evidence that the IgG anti-CCP subclasses that associate with HLA-DRB1/SE are IgG1 and IgG4 (Fig. 5) . However, the low number of patients positive for SE and IgG2 or IgG3 anti-CCP could have influenced the results. Furthermore, we found not only that IgA anti-CCP but also IgG2 anti-CCP antibodies were significantly more frequent among ever-smoking RA patients compared to never-smoking RA cases, and that this response might be independent of SE status (Fig. 5) .
It has long been known that IgG2 antibodies against antigens with repeated antigenic determinants can stimulate B cells to induce antibodies without T helper (Th) cell co-operation [33] , a field currently experiencing renewed interest [34] [35] [36] [37] . Hypothetically, this may indicate Th cellindependent formation of IgG2-and/or IgA-ACPA. Another hypothesis regarding the increase in IgG2 anti-CCP is the potential involvement of the periodontal pathogen Porphyromonas gingivalis in RA development. P. gingivalis expresses a citrullinating enzyme, porphyromonal peptidyl-arginine deiminase (PPAD), which may increase the load of citrullinated antigens that could interfere with the host's immune functions [38] . P. gingivalis has a broad range of virulence factors such as lipopolysaccharide (LPS) [39] and, interestingly, the host's general immune response to LPS is secretion of IgG2 [40] . Also, the presence of P. gingivalis is more frequent in smokers [41] , and thus one speculative explanation for the increased proportion of IgG2 anti-CCP in RA smokers could be increased P. gingivalis infection. Indeed, Mikuls et al. found that IgG2 anti-CCP, unlike the other subclasses, correlated with antibodies to P. gingivalis in RA patients [42] .
The proportion of IgG anti-CCP-positive cases in the SE 1 subgroup was significantly higher compared to the SE -subgroup regardless of IgG anti-CCP subclass and anti-CCP isotype. However, when we combined the data regarding SE and smoking and correlated it with the different IgG anti-CCP subclass, we found an increased proportion of IgG4 anti-CCP-positive cases which was not associated with smoking (Fig. 5 ). IgG4 antibody production has been associated with prolonged and/or repeated antigen exposure [43] . As antibodies to citrullinated antigens may be present long before symptom onset [44] , it is likely that exposure to disease-inducing antigens occurs for a long time, possibly explaining the high proportion of IgG4 anti-CCP-positive RA patients in our cohort. However, a contradiction to this is the fact that levels of IgG4 as well as other anti-CCP isotypes and subclasses, apart from IgG1, have been reported to decline over time in RA patients [29] . Speculatively, the high proportion of IgG4 anti-CCPpositive RA patients in our cohort could also represent an anti-inflammatory response via Fab-arm exchange effects [27] . Natural bi-specific (IgG4 anti-CCP and IgG anti-RF) antibodies have actually been identified in RA patients [45] . Natural bi-specific antibodies are postulated not to burden inflammation due to the limited ability to activate complement, but instead be a beneficial event for the patients and perhaps be a potential indicator of disease remission [45] . However, high levels of IgG4 antibodies have been shown to associate with higher disease activity and poor response to treatment [46] and IgG4 antibody may also have pathogenic properties, as seen in bullous pemphigoid [47] .
HLA-DRB1*15 is a non-SE allele that has been associated with renal involvement in Japanese RA patients [48] . The secondary form of Sj€ ogren's syndrome in RA patients has also been shown to associate with an increased frequency of HLA-DRB1*15 expression [49] . More recently, Laki et al. [21] have shown that the HLA-DRB1*15 is associated with high levels of IgG anti-CCP. In the present study we found that, among IgG2 anti-CCP-positive cases, HLA-DRB1*15 was associated with elevated levels of IgG2, again indicating the importance of genetic background for RA development. DERAA is another non-SE allele, where its presence is related to lower susceptibility of RA development [50] . This allele was found in our patient cohort, but the frequency was too low to justify any statistical calculations.
To conclude, in this cohort of well-characterized early RA patients, we describe different risk factor characteristics across the IgG anti-CCP subclasses. When we combined SE and smoking data and correlated these with IgG anti-CCP subclass data, we found that IgG1 and IgG4 anti-CCP associate with HLA-DRB1/SE. In contrast, IgG2 and IgA anti-CCP appear more dependent upon smoking. These findings further detail the contributions of genes and environment to citrulline-related immune reactions in early RA.
